Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease

Clinical Nephrology

Volumn 76, Issue 1, 2011, Pages 9-15

  Mann, J F E ^a,b   de Francisco, A ^c   Nassar, G ^d   Canaud, B ^e  

^a KfH Kidney Center   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d Renal Research Inc   (United States)

^e LAPEYRONIE HOSPITAL   (France)

Author keywords

Anemia; Darbepoetin; Epoetin; Renal disease

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; DRUG DERIVATIVE; ERYTHROPOIETIN; MACROGOL DERIVATIVE; PEGINESATIDE;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; RETROSPECTIVE STUDY; BLOOD; CHRONIC DISEASE; DRUG ADMINISTRATION; KIDNEY DISEASE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL (TOPIC);

ANEMIA; CHRONIC DISEASE; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS;

EID: 80051756834     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN106847     Document Type: Article

References (26)

1. Locatetti F, Pisoni RL, Combe C, Bommer J, Andreucci VE. et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004; 19: 121-132.
2. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005; 68: 1337-1343.
3. Boudville NC, Djurdjev O, Macdougall IC, de Francisco ALM., Deray G. et al. Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality. Clin J Am Soc Nephrol. 2009; 4: 1176-1182.
4. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol. 2006; 1: 1205-1210.
5. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD. et al. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol. 2008; 3: 133-138.
6. Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M. et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther. 1991; 50: 702-712.
7. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B. et al. Pharmacokinetics of novel erythro-poiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999; 10: 2392-2395.
8. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A. et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006; 1: 1211-1215.
9. Padhi D, Ni L, Cooke B, Marino R, Jang G. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet. 2006; 45: 503-510.
10. Jarsch M, Brandt M, Lanzendörfer M, Haselbeck A. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology. 2008; 81: 63-69.
11. de Francisco AL, Sulowicz W, Klinger M, Niemc-zyk S, Vargemezis V. et al. Continuous erythropoietin receptor activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract. 2006; 60: 1687-1696.
12. Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W. et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis. 2007; 50: 989-1000.
13. Macdougall IC, Walker R, Provenzano R, de Al-varo F, Locay H. R. et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol. 2008; 3: 337-347.
14. Provenzano R, Besarab A, Macdougall IC, Ellison D. H, Maxwell A. P. et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Nephrol. 2007; 67: 306-317.
15. Roger SD. C.E.R.A. once every 4 weeks (Q4W) corrects anaemia in patients with chronic kidney disease (CKD) not on dialysis and demonstrates comparable safety to darbepoetin alfa weekly. Poster Sa535 presented at the ERA-EDTA, Munich, Germany, 25-28 June, 2010.
16. Besarab A, Salifu MO, Lunde NM, Bansal V, Fish-bane S. et al. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Clin Ther. 2007; 29: 626-639.
17. Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG. et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant. 2008; 23: 3654-3661.
18. Kessler M, Martinez-Castelao A, Siamopoulos KC, Villa G, Spinowitz B. et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodial Int. 2010; 14: 233-239.
19. Levin NW, Fishbane S, Valdés Cañedo F, Zeig S, Nassar GM. et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet. 2007; 370: 1415-1421.
20. Locatelli F, Villa G, de Francisco AL, Albertazzi A, Adrogue HJ. et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin. 2007; 23: 969-979.
21. Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M. et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol. 2008; 28: 280-289.
22. Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B. et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007; 2: 637-646.
23. Carrera F, Lok CE, de Francisco A, Locatelli F, Mann JFE. et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant. 2010; 25:4009-4017.
24. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS. et al. Hemoglobin variability in epoetin-treat-ed hemodialysis patients. Kidney Int. 2003; 64: 1514-1521.
25. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999; 33: 63-72.
26. Saueressig U, Kwan JTC, De Cock E, Sapède C. Healthcare resource utilization for anemia management: current practice with erythropoiesis-stimulating agents and the impact of converting to once-monthly C.E.R.A. Blood Purif. 2008; 26: 537-546.